IP Library Granted Patent US 8,293,739
Granted Patent B2
US 8,293,739 · App. 13/094,667 · Granted Oct 23, 2012

Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof

Assignee: Kinex Pharmaceuticals, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,293,739
App. No.
13/094,667
Granted
Oct 23, 2012
Kind
B2
Abstract

The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy) phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.

Claims (11)

1. A composition comprising KX2-391 mesylate salt.

2. The composition of claim 1 , wherein the KX2-391 mesylate salt has a purity greater than 98.0% as determined by HPLC.

3. The composition of claim 1 , wherein the KX2-391 mesylate salt has a purity of 99.0%.

4. The composition of claim 1 , wherein the KX2-391 mesylate salt has a purity of 99.5%.

5. The composition of claim 1 , wherein the KX2-391 mesylate salt has a purity of 99.6%.

6. The composition of claim 1 , wherein the KX2-391 mesylate salt has a purity of 99.7%.

7. The composition of claim 1 , wherein the composition contains less than 2% of an impurity selected from ethyl chloride, ethanol, ethyl acetate, heptane, anisole, palladium, and combinations thereof.

8. The composition of claim 1 further comprising a pharmaceutically acceptable carrier or excipient.

9. A method of treating a disease or disorder in a subject in need thereof comprising administering a composition of claim 1 to said subject, wherein the disease or disorder is selected from colon cancer, lung cancer, prostate cancer, breast cancer, brain cancer, and psoriases.

10. The method of claim 9 , wherein the composition is administered orally.

11. The method of claim 9 , wherein the composition is administered topically.

Assignments (10)
SECURITY INTEREST Recorded Sep 16, 2022
From: ATHENEX, INC.
To: SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 061119/0681 →
SECURITY INTEREST Recorded Sep 16, 2022
From: ATNX SPV, LLC
To: SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 061119/0920 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2022
From: ATHENEX, INC.
To: ATNX SPV, LLC
Reel/Frame 061071/0086 →
SECURITY INTEREST Recorded Jun 22, 2020
From: ATHENEX, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 053005/0657 →
RELEASE OF SECURITY INTEREST Recorded Jun 19, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ATHENEX, INC.
Reel/Frame 052990/0677 →
PATENT SECURITY AGREEMENT Recorded Jul 3, 2018
From: ATHENEX, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047247/0812 →
CHANGE OF NAME Recorded Sep 21, 2015
From: KINEX PHARMACEUTICALS, INC.
To: ATHENEX, INC.
Reel/Frame 036644/0296 →
CHANGE OF NAME Recorded Sep 10, 2015
From: KINEX PHARMACEUTICALS, LLC
To: KINEX PHARMACEUTICALS, INC.
Reel/Frame 036585/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2011
From: PATRA, DEBASIS; PALMER, GRANT J.; ISBESTER, PAUL K.; SALSBURY, JONATHON
To: KINEX PHARMACEUTICALS, LLC
Reel/Frame 026218/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2011
From: HANGAUER, DAVID G., JR.; COUGHLIN, DANIEL; CODY, JEREMY A.; GALE, JONATHAN
To: KINEX PHARMACEUTICALS, LLC
Reel/Frame 026218/0608 →
Continuity (5)
Continuation 12154056 · May 19, 2008
Continuation In Part 12005792 · Dec 28, 2007
Provisional Application 60930758 · May 17, 2007
Provisional Application 60877762 · Dec 28, 2006
Related Publication 20110201611A1 · Aug 18, 2011